EP0217577A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Antibody complexes of hapten-modified diagnostic or therapeutic agents
Assignee: Hybritech Inc
•
Filing: 1986-09-12
•
Granted: —
•
Expires: 2006-09-12
Abstract
Abstract Antibody complexes comprising hapten-modified diagnostic or therapeutic agents and anti-hapten antibodies are disclosed. Administration of hapten-modified agents, complexed with suitable anti-hapten antibodies, extends the serum half-life and permits an increased concentration of such diagnostic or therapeutic agents at in vivo target sites.
Inventors
- 👤 James M. Frincke
- 👤 Damon L. Meyer
- 👤 Gary S. David
- 👤 Richard M. Bartholomew
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 19:03
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/44; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6875; A61K47/6879; A61K49/00; A61K49/06; A61K51/00; A61K51/02; A61K51/04; A61K51/0497; A61K51/08; A61K51/10; A61K51/1084; A61K51/1087; A61K51/109; A61K51/1093; C07K16/18; C07K16/28; C07K16/30; C07K16/3007; C07K16/46; C07K16/468; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/68; G01N33/6878; A61K39/00; A61K2039/505; A61K2123/00; A61K38/00; C07K2317/00; C07K2317/30; C07K2317/31; C07K2317/50; C07K2317/54; C07K2317/55; C07K2319/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
43 words
A process for preparing a pharmaceutical composition which comprises complexing a hapten-modified diagnostic or therapeutic agent with an anti-hapten antibody, said anti-hapten antibody being selected to bind said hapten-modified agent in a manner which does not substantially impair the activity of said agent.
Claim 2
Dependent Claim
43 words
A process for preparing a pharmaceutical composition which comprises complexing a hapten-modified diagnostic or therapeutic agent with an anti-hapten antibody, said anti-hapten antibody being selected to bind said hapten-modified agent in a manner which does not substantially impair the activity of said agent.
Claim 3
Dependent Claim
23 words
A process for preparing a composition as claimed in claim 1 in which said anti-hapten antibody is a monoclonal antibody or fragment thereof.
Claim 4
Dependent Claim
41 words
A process for preparing a composition as claimed in claim 2 wherein said anti-hapten antibody comprises an antibody fragment selected from the group consisting of Fab, Fab', F(ab')₂ fragments or an antibody fragment retaining the essential binding function of said antibody.
Claim 5
Dependent Claim
44 words
A process for preparing a composition as claimed in claim 2 in which said anti-hapten antibody is a chimeric antibody or hybrid monoclonal antibody having a dual specificity, one of which is directed against said hapten-modified agent and the other against a target antigen.
Claim 6
Dependent Claim
27 words
A process for preparing a composition as claimed in claim 4 in which said target antigen is a tumor-associated antigen and said hapten-modified agent has anti-tumor activity.
Claim 7
Dependent Claim
35 words
A process for preparing a composition as claimed in claim 5 in which said target antigen is selected from the group consisting of CEA, PAP, PSA, HCG, ferritin, bombesin, and melanoma-associated antigens p97 and gp240.
Claim 8
Dependent Claim
33 words
A process for preparing a composition as claimed in claim 1 wherein said hapten-modified agent is selected from the group consisting of drugs, toxins, proteins, and biological response modifiers or radio-labeled derivatives thereof.
Claim 9
Dependent Claim
29 words
A process for preparing a composition as claimed in claim 7 in which said hapten-modified agent is a drug capable of binding to a receptor at said target site.
Claim 10
Dependent Claim
29 words
A process for preparing a composition as claimed in any of claims 1 to 8 in which said hapten-modified agent and said anti-hapten antibody are complexed in vitro .
Claim 11
Dependent Claim
30 words
A process for preparing a composition as claimed in claim 1 in which said hapten-modified agent comprises mitomycin C aminobenzyl EDTA thiourea ("MAT"), a metal complex or a derivative thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.